drugset / Trial / NCT07221084

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

NCT07221084

Phase 1 Completed 21 enrolled Crinetics Pharmaceuticals Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the PK profile, safety, and tolerability of atumelnant after single and multiple once daily (QD) oral doses in healthy Japanese and Caucasian adult participants.

Timeline

Start
2025-10-28
Primary completion
2026-02-07
Completion
2026-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Atumelnant Small molecule Oral

Indications

No indication recorded.